These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703 [TBL] [Abstract][Full Text] [Related]
10. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4. Yang QE; Stephen AG; Adelsberger JW; Roberts PE; Zhu W; Currens MJ; Feng Y; Crise BJ; Gorelick RJ; Rein AR; Fisher RJ; Shoemaker RH; Sei S J Virol; 2005 May; 79(10):6122-33. PubMed ID: 15857997 [TBL] [Abstract][Full Text] [Related]
11. 2-Aminothiazolones as anti-HIV agents that act as gp120-CD4 inhibitors. Tiberi M; Tintori C; Ceresola ER; Fazi R; Zamperini C; Calandro P; Franchi L; Selvaraj M; Botta L; Sampaolo M; Saita D; Ferrarese R; Clementi M; Canducci F; Botta M Antimicrob Agents Chemother; 2014 Jun; 58(6):3043-52. PubMed ID: 24614386 [TBL] [Abstract][Full Text] [Related]
12. HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor. Bashir T; Patgaonkar M; Kumar SC; Pasi A; Reddy KV PLoS One; 2015; 10(4):e0124839. PubMed ID: 25915507 [TBL] [Abstract][Full Text] [Related]
13. Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors. Brower ET; Schön A; Freire E Biochemistry; 2010 Mar; 49(11):2359-67. PubMed ID: 20166763 [TBL] [Abstract][Full Text] [Related]
14. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors. Hamza A; Zhan CG J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901 [TBL] [Abstract][Full Text] [Related]
15. Computational studies identifying entry inhibitor scaffolds targeting the Phe43 cavity of HIV-1 gp120. Tintori C; Selvaraj M; Badia R; Clotet B; Esté JA; Botta M ChemMedChem; 2013 Mar; 8(3):475-83. PubMed ID: 23404750 [TBL] [Abstract][Full Text] [Related]
16. Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor. Vermeire K; Schols D Expert Opin Investig Drugs; 2005 Oct; 14(10):1199-212. PubMed ID: 16185162 [TBL] [Abstract][Full Text] [Related]
17. Virtual Screening, Biological Evaluation, and 3D-QSAR Studies of New HIV-1 Entry Inhibitors That Function via the CD4 Primary Receptor. Zhang C; Zhang H; Huang LS; Zhu S; Xu Y; Zhang XQ; Schooley RT; Yang X; Huang Z; An J Molecules; 2018 Nov; 23(11):. PubMed ID: 30463393 [TBL] [Abstract][Full Text] [Related]
18. Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators. Zhang S; Holmes AP; Dick A; Rashad AA; Enríquez Rodríguez L; Canziani GA; Root MJ; Chaiken IM Retrovirology; 2021 Oct; 18(1):31. PubMed ID: 34627310 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120. Curreli F; Kwon YD; Belov DS; Ramesh RR; Kurkin AV; Altieri A; Kwong PD; Debnath AK J Med Chem; 2017 Apr; 60(7):3124-3153. PubMed ID: 28266845 [TBL] [Abstract][Full Text] [Related]
20. Computational design, synthesis and evaluation of new sulphonamide derivatives targeting HIV-1 gp120. Vangala R; Sivan SK; Peddi SR; Manga V J Comput Aided Mol Des; 2020 Jan; 34(1):39-54. PubMed ID: 31792886 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]